Srinivas Rao
@srinigrao.bsky.social
Co-CEO and Co-Founder of atai Life Sciences (www.atai.life). Opinions expressed are my own.
We’re another step closer to bringing innovative new options to people living with treatment-resistant depression. Read about new Phase 2a results from atai Life Sciences & BeckleyPsytech: ir.atai.com/news-release...
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression | Atai...
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningfu...
ir.atai.com
September 23, 2025 at 1:39 PM
We’re another step closer to bringing innovative new options to people living with treatment-resistant depression. Read about new Phase 2a results from atai Life Sciences & BeckleyPsytech: ir.atai.com/news-release...
There is an urgent need for better treatment options for opioid use disorder. We're honored that atai has received this grant from the NIH, which will accelerate our ability to bring innovative new treatments to people suffering from addiction. ir.atai.com/news-release...
atai Life Sciences Awarded Grant from the National Institutes of Health | Atai Life Sciences N.V.
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder NEW YORK and AMSTERDAM...
ir.atai.com
September 18, 2025 at 9:43 PM
There is an urgent need for better treatment options for opioid use disorder. We're honored that atai has received this grant from the NIH, which will accelerate our ability to bring innovative new treatments to people suffering from addiction. ir.atai.com/news-release...
I’m pleased to share atai’s Q2 financial results and corporate updates. This quarter has been transformational for atai. We’re proud to be a leader in developing next-gen psychedelic mental health therapies.
#MentalHealth #Biotech #Q2 #Earnings
#MentalHealth #Biotech #Q2 #Earnings
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates | Atai Life Sciences N.V.
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported posi...
ir.atai.com
August 14, 2025 at 3:07 PM
I’m pleased to share atai’s Q2 financial results and corporate updates. This quarter has been transformational for atai. We’re proud to be a leader in developing next-gen psychedelic mental health therapies.
#MentalHealth #Biotech #Q2 #Earnings
#MentalHealth #Biotech #Q2 #Earnings
Q4 #Earnings update: Strong financial position following a successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. We enter 2025 in a position of strength, focused on transforming #mentalhealth. bit.ly/4ioeENc
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights | Atai Life Sciences N.V.
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical tr...
bit.ly
March 17, 2025 at 5:01 PM
Q4 #Earnings update: Strong financial position following a successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. We enter 2025 in a position of strength, focused on transforming #mentalhealth. bit.ly/4ioeENc
The first patient has been dosed in Elumina, our Ph2 trial of VLS-01 for TRD – an important milestone. With ~100M people affected and limited options, we focus on conditions with high unmet need. Looking forward to the data in Q1’26. ir.atai.life/news-release...
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression | ATAI Life Sciences N.V.
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from t...
ir.atai.life
March 12, 2025 at 5:22 PM
The first patient has been dosed in Elumina, our Ph2 trial of VLS-01 for TRD – an important milestone. With ~100M people affected and limited options, we focus on conditions with high unmet need. Looking forward to the data in Q1’26. ir.atai.life/news-release...
Milestone update: Enrollment complete in Ph2b trial of Beckley Psytech’s BPL-003 for treatment-resistant depression (TRD). Results expected mid-2025. Full announcement: bit.ly/4immzun
bit.ly
March 5, 2025 at 3:47 PM
Milestone update: Enrollment complete in Ph2b trial of Beckley Psytech’s BPL-003 for treatment-resistant depression (TRD). Results expected mid-2025. Full announcement: bit.ly/4immzun
It's so sad to read about all of the struggles that this region--where I grew up--is going through. The loss of life there is heartbreaking.
‘We know what it’s like’: How Appalachian towns are learning to help each other after floods.
grist.org/extreme-weat...
#Appalachia #Kentucky #Virginia #WestVirginia #Tennessee
grist.org/extreme-weat...
#Appalachia #Kentucky #Virginia #WestVirginia #Tennessee
'We know what it's like': How Appalachian towns are learning to help each other after floods
From the Kentucky floods to Helene and back again, people throughout Appalachia are using their experiences to help each other through disaster.
grist.org
February 25, 2025 at 9:49 PM
It's so sad to read about all of the struggles that this region--where I grew up--is going through. The loss of life there is heartbreaking.
Reposted by Srinivas Rao
Studies show that funding from the National Institutes of Health (NIH) contributed to 354 of 356 drugs (99.4%) approved by the FDA from 2010 to 2019. Recklessly slashing NIH funding will mean that patients will be waiting much longer for life-saving treatments.
February 24, 2025 at 7:21 PM
Studies show that funding from the National Institutes of Health (NIH) contributed to 354 of 356 drugs (99.4%) approved by the FDA from 2010 to 2019. Recklessly slashing NIH funding will mean that patients will be waiting much longer for life-saving treatments.
Honored to step into the role of sole CEO at atai. Thanks to @flobrand.bsky.social for his visionary leadership that brought atai to where it is today. Thrilled to build on this foundation with a strengthened leadership team. Full press release: ir.atai.life/news-release...
ir.atai.life
January 10, 2025 at 5:03 PM
Honored to step into the role of sole CEO at atai. Thanks to @flobrand.bsky.social for his visionary leadership that brought atai to where it is today. Thrilled to build on this foundation with a strengthened leadership team. Full press release: ir.atai.life/news-release...
Reposted by Srinivas Rao
December 25, 2024 at 4:33 PM
Great to see a pharmacotherapy get approved for OSA, a huge unmet medical need! This takes me back to my Cypress Bio days, where we tested a centrally acting agent in this indication in a phase 2 trial. While the trial was negative, we learned a great deal about OSA variability.
The FDA cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S.
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.
The FDA has cleared Eli Lilly’s obesity drug Zepbound as the first treatment for obstructive sleep apnea in the U.S.
buff.ly
December 21, 2024 at 5:18 PM
Great to see a pharmacotherapy get approved for OSA, a huge unmet medical need! This takes me back to my Cypress Bio days, where we tested a centrally acting agent in this indication in a phase 2 trial. While the trial was negative, we learned a great deal about OSA variability.
Reposted by Srinivas Rao
This is an important biotech result - and a disappointing one.
There's a desperate need for effective pain treatments that could be an alternative to opioids.
Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.
www.statnews.com/2024/12/19/v...
There's a desperate need for effective pain treatments that could be an alternative to opioids.
Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.
www.statnews.com/2024/12/19/v...
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
www.statnews.com
December 19, 2024 at 1:08 PM
This is an important biotech result - and a disappointing one.
There's a desperate need for effective pain treatments that could be an alternative to opioids.
Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.
www.statnews.com/2024/12/19/v...
There's a desperate need for effective pain treatments that could be an alternative to opioids.
Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.
www.statnews.com/2024/12/19/v...
Reposted by Srinivas Rao
Psilocybin increases emotional empathy in patients with major depression
www.researchgate.net/publication/...
www.researchgate.net/publication/...
(PDF) Psilocybin increases emotional empathy in patients with major depression
PDF | Empathy plays a crucial role in interpersonal relationships and mental health. It is decreased in a variety of psychiatric disorders including... | Find, read and cite all the research you need ...
www.researchgate.net
December 18, 2024 at 9:31 PM
Psilocybin increases emotional empathy in patients with major depression
www.researchgate.net/publication/...
www.researchgate.net/publication/...
Congratulations to the Beckley Psytech team on the promising Phase 2a proof-of-concept results for ELE-101. The safety and efficacy signals are encouraging. We're proud to support Beckley Psytech as we continue our mission to develop scalable interventional psychiatry treatments for depression.
Beckley Psytech announces positive topline results from Phase IIa study of ELE-101 (IV psilocin benzoate) for Major Depressive Disorder
ELE-101 is Beckley Psytech's patent-protected synthetic intravenous (IV) formulation of psilocin benzoate designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, a...
www.beckleypsytech.com
December 16, 2024 at 4:39 PM
Congratulations to the Beckley Psytech team on the promising Phase 2a proof-of-concept results for ELE-101. The safety and efficacy signals are encouraging. We're proud to support Beckley Psytech as we continue our mission to develop scalable interventional psychiatry treatments for depression.
As an engineer turned physician, I’m driven by solving complex problems - few are as urgent as developing new treatments for mental health disorders.
Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...
Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...
A Pragmatic Approach to Psychedelic Drug Development
open.spotify.com
December 10, 2024 at 8:45 PM
As an engineer turned physician, I’m driven by solving complex problems - few are as urgent as developing new treatments for mental health disorders.
Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...
Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...
Reposted by Srinivas Rao
December 8, 2024 at 11:07 PM
Reposted by Srinivas Rao
We’ve come full circle. Sickness and death - from milk specifically - in the 19th century was one of the single biggest drivers leading to the establishment of the FDA
The CEO of Raw Farm—whose milk is contaminated with bird flu—says RFKjr’s transition team asked him to apply for the position of FDA advisor on Raw Milk Policy and Standards Development.
California suspends distribution of Raw Farm raw milk products after bird flu detection | CNN
Distribution of Raw Farm raw milk products has been suspended after bird flu virus was found in milk samples, the California Department of Food and Agriculture said.
www.cnn.com
December 5, 2024 at 2:41 PM
We’ve come full circle. Sickness and death - from milk specifically - in the 19th century was one of the single biggest drivers leading to the establishment of the FDA
Reposted by Srinivas Rao
This essay has been long overdue. Chapeau to Tom Pollock for writing it.
academic.oup.com/brain/advanc...
academic.oup.com/brain/advanc...
Why inflammatory reductionism is a threat to psychiatry (and the rest of medicine)
Thomas Pollak explores the emergence of a new worldview which attempts to explain all manner of ills as the result of inflammation or immune dysfunction. H
academic.oup.com
November 21, 2024 at 7:04 PM
This essay has been long overdue. Chapeau to Tom Pollock for writing it.
academic.oup.com/brain/advanc...
academic.oup.com/brain/advanc...
@daphnezohar.bsky.social, great to see you on BlueSky and to see you in person at CNS Summit!
November 24, 2024 at 8:28 PM
@daphnezohar.bsky.social, great to see you on BlueSky and to see you in person at CNS Summit!
Reposted by Srinivas Rao
‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
Many appear cautiously optimistic about Trump’s intended pick
www.statnews.com/2024/11/23/m...
Many appear cautiously optimistic about Trump’s intended pick
www.statnews.com/2024/11/23/m...
‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
“We dodged a bullet”: Biotech and pharma react to selection of Marty Makary for FDA commissioner.
www.statnews.com
November 23, 2024 at 5:31 PM
‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
Many appear cautiously optimistic about Trump’s intended pick
www.statnews.com/2024/11/23/m...
Many appear cautiously optimistic about Trump’s intended pick
www.statnews.com/2024/11/23/m...
Reposted by Srinivas Rao
STAT’s @katiepalmer.bsky.social documents whet feels very palpable to me: Science and med 🧬🧪twitter moving rapidly to Blue Sky social. Happy to see so many former connections here. www.statnews.com/2024/11/21/b...
Bluesky is the new destination for X/Twitter’s health and science community. Here's why
#MedTwitter is migrating en masse from X to Bluesky, suddenly making it an essential hub for scientific discourse. Here's why.
www.statnews.com
November 21, 2024 at 2:01 PM
STAT’s @katiepalmer.bsky.social documents whet feels very palpable to me: Science and med 🧬🧪twitter moving rapidly to Blue Sky social. Happy to see so many former connections here. www.statnews.com/2024/11/21/b...
Sigh
in case you were wondering how things were going over at the other place
November 18, 2024 at 4:47 AM
Sigh
Reposted by Srinivas Rao
I’ve seen enough to make a call: Bluesky is going to be a legit competitor to Twitter.
Sweet.
Sweet.
November 17, 2024 at 1:59 AM
I’ve seen enough to make a call: Bluesky is going to be a legit competitor to Twitter.
Sweet.
Sweet.
Reposted by Srinivas Rao
